Goodwin Advises Engitix on Strategic Collaboration With GSK for £44.5 Million Upfront and Up to £118 Million in Milestones
The Life Sciences team advised Engitix Ltd. (“Engitix”) on a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets driving liver fibrosis regression. Under the terms of the agreement, Engitix is eligible to receive up to £44.5 million in upfront and near-term payments, as well as up to £118 million per target in downstream milestone payments, in addition to tiered low-single-digit royalties on future product sales. Engitix will develop human ECM-based disease models and generate high-resolution translational multi-omics datasets to uncover novel targets associated with fibrosis resolution in liver disease. GSK will have the option to license assays, datasets, and targets arising from the collaboration, and GSK will lead any further research, development, and commercialization activities on targets discovered and validated in the collaboration.
Engitix is the global leader in ECM-based drug discovery and development, delivering life-changing therapies to patients with chronic diseases.
The Goodwin team was led by Tim Worden and Lucy Charlton.
For more information on the deal, please read the press release.